Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.46 |
| ▸ | MELK | Q14680 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514434 | 0.95 | ASIC3 (0.41) | PNMTMELK | |
| SCHEMBL5256841 | 0.86 | PNMT (0.48) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1076918 | 0.86 | PPARA (0.51) | PNMT | |
| SCHEMBL4982190 | 0.81 | PPARA (0.45) | PNMT | |
| SCHEMBL12151279 | 0.78 | PPARA (0.53) | ADRA2AADRA2BADRA2C | |
| SCHEMBL4514738 | 0.77 | PARP11 (0.49) | — | |
| SCHEMBL4518538 | 0.77 | PARP10 (0.49) | — | |
| SCHEMBL746109 | 0.75 | HTR2C (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29558442 | 0.75 | HTR2C (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1648356 | 0.75 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| EP-1979347-A2 | POLYCYCLIC 1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | PPARG, PPARD, PPARA | PNMT 2445/4885MELK 1245/4885ADRA2A 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.